Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
LUCASSIN (Ikaria Australia Pty Ltd)
Product name
LUCASSIN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
201 working days (255)
Active ingredients
terlipressin
Registration type
EOI
Indication
LUCASSIN (injection) is now also indicated for the treatment of bleeding oesophageal varices.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.